Clinical Trial Update: A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer [Phase 3]

View source ↗

Summary

This Phase 3 trial assesses atezolizumab plus nab-paclitaxel for unresectable locally advanced or metastatic PD-L1-positive triple-negative breast cancer and ha…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• Tecentriq (atezolizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Triple-Negative Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2025-12-26